Daily Traders Edge

: Amgen’s new cancer drug faces questions about competition

September 15
14:36 2022

Lumakras had mixed results in a closely watched clinical trial comparing the drug to docetaxel. Analysts wonder if Mirati Therapeutics’ drug will do better.

Continue Reading At MarketWatch

Related Articles

Newsletter Signup

Sign up for our free newsletter